1
TITLE: Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)  Full Text
AUTHORS: Francis Levi; Abdoulaye Karaboue; Raphael Saffroy; Christophe Desterke; Valerie Boige; Denis Smith; Mohamed Hebbar; Pasquale Innominato; Julien Taieb; Carlos Carvalho; Rosine Guimbaud; Christian Focan; Mohamed Bouchahda; Rene Adam; Michel Ducreux; Gerard Milano; Antoinette Lemoine;
PUBLISHED: 2017, SOURCE: BRITISH JOURNAL OF CANCER, VOLUME: 117, ISSUE: 7
INDEXED IN: WOS
2
TITLE: Early tumour response as a survival predictor in previously-treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer  Full Text
AUTHORS: Mohamed Bouchahda; Valerie Boige; Denis Smith; Abdoulaye Karaboue; Michel Ducreux; Mohamed Hebbar; Celine Lepere; Christian Focan; Rosine Guimbaud; Pasquale Innominato; Sameh Awad; Carlos Carvalho; Salvatore Tumolo; Stephanie Truant; Thierry De Baere; Denis Castaing; Philippe Rougier; Jean Francois Morere; Julien Taieb; Rene Adam; Francis Levi; ...More
PUBLISHED: 2016, SOURCE: EUROPEAN JOURNAL OF CANCER, VOLUME: 68
INDEXED IN: WOS
3
TITLE: DYPD genotyping to predict toxicity in patients with stage III colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy in the PETACC-8 phase III trial
AUTHORS: Valerie Boige; Marc Vincent; Philippe Alexandre; Jan Stoehlmacher; Sabine Tejpar; Stefania Landolfi; Karine Le Malicot; Richard Greil; Pieter Jan A R Cuyle; Mette K N Yilmaz; Roger Faroux; Axel Matzdorff; Ramon Salazar; Evaristo Sanches; Laurent Mineur; Come Lepage; Julien Taieb; Pierre Laurent Puig;
PUBLISHED: 2015, SOURCE: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 33, ISSUE: 15
INDEXED IN: WOS
4
TITLE: Final results of first European phase II trial of intravenous cetuximab (Cet) and hepatic artery infusion of irinotecan, 5-fluorouracil, and oxaliplatin in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after systemic treatment failure (OPTILIV, NCT00852228).
AUTHORS: Francis Levi; Valerie Boige; Mohamed Hebbar; Denis Smith; Celine Lepere; Focan, CNJ; Rosine Guimbaud; Carlos Carvalho; Salvatore Tumolo; Pasquale F Innominato; Yves Ajavon; Stephanie Truant; Denis Castaing; Thierry De Baere; Francis Kunstlinger; Abdoulaye Karaboue; Mohamed Bouchahda; Philippe R Rougier; Rene Adam; Michel Ducreux;
PUBLISHED: 2013, SOURCE: Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO) in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 31, ISSUE: 4
INDEXED IN: WOS